Lipid Lowering Therapy – My Endo Consult

OVERVIEW OF LIPID-LOWERING AGENTS

Main Classes:
1. Cholesterol absorption inhibitors
2. 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins)
3. Bile acid sequestrants
4. Nicotinic acid
5. Fibric acid derivatives
6. Fish oil (omega-3 fatty acids)
Key Overall Benefits:
- Lowering harmful lipids (LDL cholesterol, triglycerides)
- Potentially reducing atherosclerosis and stabilizing plaques
- Improving endothelial function
- Decreasing thrombogenesis

Example: Ezetimibe
Mechanism:
- Blocks cholesterol absorption at the brush border of the intestine
- Targets Niemann-Pick C1–like 1 (NPC1L1) proteins
Effect:
- Lowers serum low-density lipoprotein (LDL) cholesterol by ~17%
- Has additive LDL-lowering effects when combined with statins
Selectivity:
- Does not affect absorption of triglycerides or fat-soluble vitamins

Mechanism:
- Competitive inhibitors of the enzyme HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis
- Decreased intracellular cholesterol → upregulation of LDL receptor turnover
Lipid Effects:
- Lowers serum LDL cholesterol by 30–60%
- Decreases small dense LDL (more atherogenic)
- Typically lowers triglycerides by 20–40%
- Increases HDL cholesterol by 5–10%
Examples:
- Lovastatin, Simvastatin, Pravastatin, Fluvastatin, Atorvastatin, Pitavastatin, Rosuvastatin

Examples: Cholestyramine, Colestipol, Colesevelam
Mechanism:
- Bind bile acids in the intestine → interrupt normal (90%) reabsorption
- Depleted bile acids = increased LDL receptor expression in hepatocytes
Effects:
- Reduce serum LDL cholesterol by 10–24%
- Additive effects with statins (can further lower LDL)
Specific Consideration:
- May affect absorption of other drugs or nutrients if taken simultaneously

Mechanism:
- Decreases hepatic production of very low-density lipoproteins (VLDL)
- Reduces lipolysis to LDL
- Enhances HDL cholesterol by inhibiting its clearance
Effects:
- Increases HDL by up to 35%
- Lowers LDL and triglycerides to varying degrees
Formulations:
- Immediate-release (crystalline)
- Sustained-release
Clinical Note:
- Common side effect: Flushing (can be mitigated with aspirin pre-treatment)

Examples: Gemfibrozil, Fenofibrate
Mechanism:
- Activate peroxisome proliferator–activated receptor-α (PPAR-α)
- Decrease hepatic VLDL secretion
- Stimulate lipoprotein lipase (LPL) activity
- Downregulate apolipoprotein (apo) CIII expression
Effects:
- Lower triglycerides by 35–50%
- Increase HDL by 15–25%
- May modestly lower LDL or have variable LDL effects depending on the baseline lipid profile

Active Components:
- Eicosapentaenoic acid (EPA, 20:5n-3)
- Docosahexaenoic acid (DHA, 22:6n-3)
Mechanism:
- Exact action not fully clarified
- Decrease hepatic secretion of triglycerides (likely by reducing VLDL production)
Effects:
- Lowers serum triglycerides by 20–50% (at doses ~3–4 g/day)
- Can slightly raise HDL
- May shift LDL toward less dense forms

Combination therapy:
- Certain agents (e.g., ezetimibe + statin, or bile acid sequestrant + statin) have additive LDL-lowering effects.
Beyond Lipid Lowering:
- Many lipid-lowering drugs (especially statins) have pleiotropic effects:
  - Plaque stabilization
  - Anti-inflammatory properties
  - Improved endothelial function

Lifestyle modifications (for all patients with elevated LDL cholesterol):
- Regular aerobic exercise
- Prudent diet (low in saturated fat, high in fiber)
- Weight loss in overweight individuals
Pharmacologic therapy depends on:
- Primary prevention (no coronary heart disease [CHD])
- Secondary prevention (presence of CHD or CHD risk equivalent)

When to Treat:
- If LDL remains high despite lifestyle measures
- If CHD risk assessment (e.g., Framingham) indicates pharmacologic treatment
First-Line Therapy:
- HMG-CoA reductase inhibitors (statins)
- Statins lower CHD risk by 20–30%
Typical Statin Doses:
- Atorvastatin 10 mg
- Lovastatin, Pravastatin, or Simvastatin 20 mg
Expected Lipid Changes:
- LDL ↓ by 30–60%
- Some statins (e.g., atorvastatin, rosuvastatin) also lower triglycerides
Adverse Effects:
- Potential hepatic enzyme elevations
- Rare diffuse myalgias
- Rhabdomyolysis (1 per 15 million prescriptions), more common if combined with:
  - Fibrates (notably gemfibrozil > fenofibrate)
  - Cyclosporine

Patient Population:
- Individuals with CHD or CHD equivalent (e.g., diabetes)
- Risk of future myocardial infarction is 20× higher in these patients
Benefits of Cholesterol Lowering in CHD:
- 13–16% reduction in mortality
- Slows progression and may induce regression of coronary atherosclerosis
- Greatest benefit when LDL <100 mg/dL
Treatment Approach:
- Statins (titrate every 6 weeks to achieve LDL <100 mg/dL)
- In acute MI setting: high-dose statin (e.g., atorvastatin 80 mg/d) to target LDL <70 mg/dL
- If LDL goal not met with statin alone:
  - Add cholesterol absorption inhibitor (ezetimibe)
  - Or add bile acid sequestrant
- Statin intolerance (myopathy):
  - Consider alternative agents or pravastatin (lower myopathy risk)

Low HDL is common in patients with premature CHD
Lifestyle Measures to increase HDL:
- Exercise
- Weight loss (if obese)
- Smoking cessation
Medications that may help increase HDL by 15–30%:
- Nicotinic acid
- Gemfibrozil
- Estrogen replacement therapy in postmenopausal women
Drugs that lower HDL (e.g., androgens, benzodiazepines, β-blockers) should be discontinued if possible

Rationale:
- Triglyceride-rich lipoproteins (VLDL, chylomicrons) also transport cholesterol
- Managing hypertriglyceridemia helps correct hypercholesterolemia
Combined High LDL + High Triglycerides:
- Statins often first choice
Triglycerides >1000 mg/dL:
- Risk of chylomicronemia syndrome (pancreatitis, eruptive xanthomas, lipemia retinalis)
- Immediate therapy (e.g., fibrates, nicotinic acid) to prevent pancreatitis

Frequency:
- Every 6–8 weeks until LDL goal is achieved
- Every 6–12 months thereafter
Liver Function Tests:
- Check at time of blood sampling with each dose change (especially for statins)